These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16606335)

  • 1. Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice.
    Mutoh M; Niho N; Wakabayashi K
    Biol Chem; 2006 Apr; 387(4):381-5. PubMed ID: 16606335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice.
    Niho N; Mutoh M; Takahashi M; Tsutsumi K; Sugimura T; Wakabayashi K
    Proc Natl Acad Sci U S A; 2005 Feb; 102(8):2970-4. PubMed ID: 15710887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands.
    Niho N; Takahashi M; Kitamura T; Shoji Y; Itoh M; Noda T; Sugimura T; Wakabayashi K
    Cancer Res; 2003 Sep; 63(18):6090-5. PubMed ID: 14522940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma.
    Takeuchi Y; Takahashi M; Sakano K; Mutoh M; Niho N; Yamamoto M; Sato H; Sugimura T; Wakabayashi K
    Carcinogenesis; 2007 Aug; 28(8):1692-6. PubMed ID: 17449904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand.
    Niho N; Takahashi M; Shoji Y; Takeuchi Y; Matsubara S; Sugimura T; Wakabayashi K
    Cancer Sci; 2003 Nov; 94(11):960-4. PubMed ID: 14611672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice.
    Mutoh M; Niho N; Komiya M; Takahashi M; Ohtsubo R; Nakatogawa K; Ueda K; Sugimura T; Wakabayashi K
    Carcinogenesis; 2008 Apr; 29(4):824-9. PubMed ID: 18258607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of hyperlipidemia by indomethacin in Min mice.
    Niho N; Mutoh M; Komiya M; Ohta T; Sugimura T; Wakabayashi K
    Int J Cancer; 2007 Oct; 121(8):1665-9. PubMed ID: 17546600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis.
    Yu J; Chu ES; Hui AY; Cheung KF; Chan HL; Leung WK; Farrell GC; Sung JJ
    Biochem Biophys Res Commun; 2007 Apr; 356(1):53-9. PubMed ID: 17350593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of peroxisome proliferator-activated receptor-α (PPARα) suppresses postprandial lipidemia through fatty acid oxidation in enterocytes.
    Kimura R; Takahashi N; Murota K; Yamada Y; Niiya S; Kanzaki N; Murakami Y; Moriyama T; Goto T; Kawada T
    Biochem Biophys Res Commun; 2011 Jun; 410(1):1-6. PubMed ID: 21640707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible involvement of hyperlipidemia in increasing risk of colorectal tumor development in human familial adenomatous polyposis.
    Mutoh M; Akasu T; Takahashi M; Niho N; Yoshida T; Sugimura T; Wakabayashi K
    Jpn J Clin Oncol; 2006 Mar; 36(3):166-71. PubMed ID: 16478792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase of oxidant-related triglycerides and phosphatidylcholines in serum and small intestinal mucosa during development of intestinal polyp formation in Min mice.
    Ikeda K; Mutoh M; Teraoka N; Nakanishi H; Wakabayashi K; Taguchi R
    Cancer Sci; 2011 Jan; 102(1):79-87. PubMed ID: 20946475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of lipoprotein lipase activators bezafibrate and NO-1886, on B16 melanoma-induced cachexia in mice.
    Kawamura I; Yamamoto N; Sakai F; Yamazaki H; Goto T
    Anticancer Res; 1999; 19(5B):4099-103. PubMed ID: 10628360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer.
    Shigeto T; Yokoyama Y; Xin B; Mizunuma H
    Oncol Rep; 2007 Oct; 18(4):833-40. PubMed ID: 17786343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.
    Berthiaume M; Laplante M; Tchernof A; Deshaies Y
    Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wild bitter gourd extract up-regulates mRNA expression of PPARα, PPARγ and their target genes in C57BL/6J mice.
    Chao CY; Yin MC; Huang CJ
    J Ethnopharmacol; 2011 Apr; 135(1):156-61. PubMed ID: 21392566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor.
    Teraoka N; Mutoh M; Takasu S; Ueno T; Yamamoto M; Sugimura T; Wakabayashi K
    Cancer Prev Res (Phila); 2011 Mar; 4(3):445-53. PubMed ID: 21233289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
    Swamy MV; Patlolla JM; Steele VE; Kopelovich L; Reddy BS; Rao CV
    Cancer Res; 2006 Jul; 66(14):7370-7. PubMed ID: 16849589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of anti-obesity effects of the pomegranate leaf extract in high-fat diet induced obese mice.
    Lei F; Zhang XN; Wang W; Xing DM; Xie WD; Su H; Du LJ
    Int J Obes (Lond); 2007 Jun; 31(6):1023-9. PubMed ID: 17299386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.
    Toba H; Miki S; Shimizu T; Yoshimura A; Inoue R; Sawai N; Tsukamoto R; Murakami M; Morita Y; Nakayama Y; Kobara M; Nakata T
    Eur J Pharmacol; 2006 Nov; 549(1-3):124-32. PubMed ID: 16979161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.